#1 Clinical Trials Search in Europe

ALKYLATING AGENTS

Clinical trials investigating ALKYLATING AGENTS are studying treatment options for people with myelofibrosis, especially those with intermediate-2 or high-risk disease. The main goal is to compare outcomes such as overall survival and see how well current treatment choices work in patients whose disease is not responding to JAK-inhibitor treatment.

Table of Contents

Trial overview

The provided trial data include one authorised interventional study, which means researchers assign treatments and then measure the results in patients.[1] The study is in myelofibrosis, a blood cancer that affects the bone marrow and can cause serious illness.[1]

The trial title says it compares current available therapies with imetelstat for people with intermediate-2 or high-risk myelofibrosis who are not responding to JAK-inhibitor treatment.[1] The brief summary says the main goal is to compare overall survival in people with relapsed or refractory disease.[1]

Who is being studied

This study is for people with intermediate-2 or high-risk myelofibrosis.[1] These risk groups describe more serious disease, so the trial focuses on patients who may need stronger treatment options.[1]

The study also includes patients whose disease is relapsed or refractory after JAK-inhibitor treatment.[1] Relapsed means the disease has returned, and refractory means it is not responding to treatment.[1]

What the study compares

The trial compares current available therapies with imetelstat.[1] This kind of comparison helps researchers see whether one treatment approach leads to better outcomes than the other.[1]

The intervention list shows imetelstat given intravenously, which means through a vein.[1] The data do not provide further details about the other treatment options, only that they are current available therapies.[1]

Study phase and size

This is a Phase 3 trial.[1] Phase 3 studies are later-stage trials that usually compare treatments in a larger group of patients.[1]

The planned enrollment is 354 participants.[1] A study of this size can help researchers compare results more reliably across treatment groups.[1]

Main endpoint

The primary outcome is overall survival.[1] Overall survival means the time from randomization to death from any cause.[1]

This endpoint is important because it shows whether one treatment strategy helps people live longer than another.[1] In this study, researchers are using overall survival to judge the main benefit of treatment.[1]

What the results may mean for patients

From the trial data, the main question is whether the study treatment approach can improve survival for people with difficult-to-treat myelofibrosis.[1] The study is focused on patients whose disease has not responded well to JAK-inhibitor treatment, so it targets a group with limited options.[1]

The trial is authorised, which means it has been approved to move forward.[1] Because the study is still a clinical trial, its purpose is to test and compare outcomes rather than to give a final answer about treatment success.[1]

Trial ID Phase Condition studied Status Enrollment
NCT04576156 Phase 3 Myelofibrosis Authorised 354

FAQ

  • What clinical trial is listed for ALKYLATING AGENTS? The listed trial is a Phase 3 study in myelofibrosis. It compares current available therapies with imetelstat in people whose disease is not responding to JAK-inhibitor treatment.
  • Who can take part in this trial? The trial is for adults with intermediate-2 or high-risk myelofibrosis. Participants must have disease that is relapsed or refractory, which means it has come back or is not responding to treatment.
  • What is the main goal of the study? The main goal is to compare overall survival, which means how long people live after starting the study treatment. This helps show whether one treatment approach works better than another.
  • What phase is the trial? This is a Phase 3 trial. Phase 3 studies are usually larger studies that compare a new treatment with current standard options.
  • How many people are planned for the study? The trial plans to enroll 354 participants. This size helps researchers compare treatment results in a larger group of patients.

Ongoing Clinical Trials on ALKYLATING AGENTS

  • Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Denmark France Germany +5

Glossary

  • Myelofibrosis: A type of blood cancer that affects the bone marrow, where blood cells are made.
  • Intermediate-2 risk: A disease risk group that shows a more serious form of illness than lower-risk disease.
  • High-risk: A group used to describe disease that is more severe and may need more urgent treatment.
  • JAK-inhibitor treatment: A treatment approach that works on a specific pathway used in myelofibrosis. In this trial, patients are not responding well to it.
  • Relapsed: When a disease returns after treatment.
  • Refractory: When a disease does not respond to treatment.
  • Phase 3: A later stage of clinical research that usually compares treatments in a larger group of patients.
  • Overall survival: The length of time people live after a treatment starts or after randomization in a study.
  • Randomization: A process where participants are assigned to treatment groups by chance.
  • Current available therapies: The treatments already available to patients and used as the comparison group in the study.
  • Interventional study: A study in which researchers assign a treatment to see how it affects health outcomes.

References